MedTrace Logo

Pharmacokinetics of Apixaban in Nephrotic Syndrome

NCT02599532 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2019-07-24

No results posted yet for this study

Summary

This study is to investigate the pharmacokinetics and pharmacodynamics of apixaban in nephrotic syndrome.

Conditions

  • Nephrotic Syndrome
  • Proteinuria

Interventions

DRUG

apixaban

Study subjects will be given a single-dose of apixaban 10 mg.

Sponsors & Collaborators

  • North Carolina Translational and Clinical Sciences Institute

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Daniel Crona, PharmD, PhD · University of North Carolina, Chapel Hill

  • Vimal Derebail, MD, MPH · University of North Carolina, Chapel Hill

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-30
Primary Completion
2019-06-28
Completion
2019-06-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02599532 on ClinicalTrials.gov